Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
- Registration Number
- NCT02238158
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 595
Inclusion Criteria
- Primarily patients of both gender, older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
- Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion Criteria
• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhalets
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic Obstructive Pulmonary Disease Atrovent® inhalets -
- Primary Outcome Measures
Name Time Method Investigator assessment of improvement of the clinical picture rated on a 6-point symptom profile Up to 12 months after first study drug administration
- Secondary Outcome Measures
Name Time Method Assessment of tolerability by patient on a 4-point scale Up to 12 months after first study drug administration Number of patients with adverse drug reactions Up to 12 months after first study drug administration Assessment of tolerability by investigator on a 4-point scale Up to 12 months after first study drug administration Assessment of efficacy by investigator on a 4-point scale Up to 12 months after first study drug administration Assessment of efficacy by patient on a 4-point scale Up to 12 months after first study drug administration